Business services providers thrive by solving complex operational challenges for their clients, allowing them to focus on ...

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

A new Equifax® (NYSE:EFX) survey shows that human resources (HR) leaders are facing challenges using technology innovation to ...

Generation IM’s Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...